Verona Pharma plc (NASDAQ:VRNA) Shares Acquired by Legato Capital Management LLC

Legato Capital Management LLC boosted its stake in Verona Pharma plc (NASDAQ:VRNAFree Report) by 26.1% during the fourth quarter, Holdings Channel.com reports. The fund owned 24,329 shares of the company’s stock after purchasing an additional 5,032 shares during the quarter. Legato Capital Management LLC’s holdings in Verona Pharma were worth $484,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in VRNA. Citigroup Inc. acquired a new position in shares of Verona Pharma during the 1st quarter worth approximately $1,841,000. Renaissance Technologies LLC purchased a new position in Verona Pharma during the second quarter worth approximately $118,000. Goldman Sachs Group Inc. acquired a new position in Verona Pharma during the second quarter worth $49,000. Envestnet Asset Management Inc. purchased a new stake in Verona Pharma in the 3rd quarter valued at $165,000. Finally, Cubist Systematic Strategies LLC acquired a new stake in shares of Verona Pharma in the 3rd quarter worth $438,000. Hedge funds and other institutional investors own 85.88% of the company’s stock.

Verona Pharma Stock Up 0.8 %

NASDAQ VRNA opened at $16.07 on Monday. The stock has a fifty day simple moving average of $17.04 and a 200-day simple moving average of $16.25. Verona Pharma plc has a twelve month low of $11.83 and a twelve month high of $23.81. The company has a current ratio of 33.33, a quick ratio of 33.33 and a debt-to-equity ratio of 0.20.

Verona Pharma (NASDAQ:VRNAGet Free Report) last posted its earnings results on Thursday, February 29th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.07. On average, sell-side analysts expect that Verona Pharma plc will post -1.23 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on VRNA. Wedbush reissued an “outperform” rating and set a $33.00 price target on shares of Verona Pharma in a research report on Friday, March 1st. HC Wainwright reissued a “buy” rating and issued a $32.00 price target on shares of Verona Pharma in a research note on Monday, March 4th.

Check Out Our Latest Stock Analysis on VRNA

Verona Pharma Company Profile

(Free Report)

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.

Featured Articles

Want to see what other hedge funds are holding VRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Verona Pharma plc (NASDAQ:VRNAFree Report).

Institutional Ownership by Quarter for Verona Pharma (NASDAQ:VRNA)

Receive News & Ratings for Verona Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma and related companies with MarketBeat.com's FREE daily email newsletter.